PD-1/PD-L1 inhibitor therapy: transitioning from a second-line to a first-line therapy for non-small cell lung cancer
Recently, monoclonal antibodies targeting the programmed death 1 (PD-1)/PD ligand 1 (PD-L1) pathway have dramatically changed the treatment paradigm for non-small cell lung cancer (NSCLC). Several PD-1/PD-L1 inhibitors have been validated as second-line therapies for NSCLC, and are now being activel...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sungkyunkwan University School of Medi
2017-03-01
|
| Series: | Precision and Future Medicine |
| Subjects: | |
| Online Access: | http://www.pfmjournal.org/upload/pdf/pfm-2017-00066.pdf |